ArticleCancer medicine2019

Sequential cetuximab/bevacizumab therapy is associated with improved outcomes in patients with wild-type KRAS exon 2 metastatic colorectal cancer.

Hung-Chih Hsu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.